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Abstract
The incidence of cancer is on the rise globally. Under particu-
lar circumstances, patients are willing to travel abroad for 
healthcare treatments. We know relatively little however 
about patients travelling overseas for cancer-related screen-
ing, diagnosis and treatment. Where do patients go, for what 
treatments, what are their motivations, decision-making 
processes and treatment experiences? What do we know 
about patient safety and risk, and outcomes? More broadly, 
what are the ethical and legal implications? This review pre-
sents the first published assessment of what we term ‘trans-
national oncology treatment’, defined as patients travelling 
overseas or across borders for cancer screening, diagnosis 
and treatment. The review undertakes detailed search and 
retrieval of the literature, using an accepted scoping review 
method. We present a narrative review of existing knowl-
edge and themes, identifying coverage and gaps. There is a 
five-fold agenda for future investigation: trajectories and 
itineraries; in depth focus on treatment decisions, experi-
ences and outcomes; locating patient travel within wider 
health system analysis; exploration of professional perspec-
tives and coordination; and situating travel within the con-
text of health trade. Such an agenda is multidisciplinary and 
wide-ranging, encompassing epidemiology, health econom-
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1 | BACKGROUND
There is a robust evidence base on the incidence, costs, and implications of cancers globally. In 2019, there were 17 
million new cases of cancer diagnosed worldwide, one in six deaths was due to the disease, and 70% occurred in low- 
and middle-income countries.1 Estimated annual costs of cancer were US$ 116 billion.2
Whilst the total number of cancer deaths globally is increasing as a result of population growth and ageing, death 
rates are in fact falling as a result of earlier detection and better treatments. For developed health systems within 
the Organisation for Economic Co-operation and Development, the availability and waiting times for cancer screen-
ing, diagnosis and treatment, alongside evidence of survival-rates, are markers of national system performance and 
equity.3 Low- and middle-income countries suffer disproportionately from cancers (and cancers with causes due to 
infection and tobacco), and the unequal distribution of cancer care resources in these countries produce global onco-
logical disparities in diagnosis and treatment.4,5 Developed health systems continuously advance cancer treatments 
and technology – diagnostics, new surgical and radiography techniques, and pharma and gene therapy. Patients and 
patient groups exert pressure to make interventions widely available, and regulators assess treatment safety and val-
ue for money.6,7
Contemporary patient mobility has burgeoned given transformations of economic production, trade patterns, 
travel, regional political and trade cooperation, treatment innovation, web-based resources, and socio-cultural trends 
such as patient voice and consumerism. Scholarship has identified patients travelling for treatments including elective 
surgery, transplantation, cosmetic treatment, fertility and dental care. Over the past decade, literature has addressed 
diverse treatments and travel routes.8–13 Yet as Kaspar (p.125) notes,14 ‘research on medical travel has hitherto largely 
underestimated cancer’. The lacunae is surprising given the prognosis of cancer increases demand for timely, effective 
and, what are perceived as, higher quality treatments. On the supply side, investment in high-end cancer treatment 
by private and public healthcare are premised, at least in part, on international patients.15 We review the broad field 
of cancer travel overseas to clarify the current state of published research and commentary, and to identify the sorts 
of things we know and do not know. In noting the uneven coverage of current research literature, we identify five 
key themes for future attention: trajectories and itineraries; in depth focus on treatment decisions, experiences and 
outcomes; locating patient travel within wider health system analysis; professional perspectives and coordination; 
and situating travel within the context of health trade. The article will be structured as follows. First, an overview of 
the research problem and the search approach used to address it. Second, an overview of the main themes: Itineraries 
(who travels, where, for what and why); Treatment processes and challenges; Patient safety, risk and outcomes; Ethi-
cal, legal and regulatory considerations. Third, we discuss the significance of findings and their implications for future 
research directions.
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ics, health policy ethics, health politics, health management, 
and health policy.
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2 | RESEARCH PROBLEM AND METHOD
This narrative review brings together existing literature on transnational oncology treatment defined as patients travel-
ling overseas or across borders for cancer screening, diagnosis and treatment. The dataset of this scoping review con-
sists of a systemic search that identified 104 articles related to cross-border cancer treatments from four electronic 
databases, namely ProQuest, Web of Science, Scopus (where Medline is covered) and EMBASE.
The initial search was conducted on May 2020 with the search terms ‘cancer/tumour’ in conjunction with ‘medi-
cal travel’, ‘medical tourism’, ‘treatment & overseas/abroad’, ‘cross-border & care’, ‘cross-border & travel’ and ‘foreign 
country’. The range of this search covered academic articles (book chapters, conference papers, dissertations and 
scholarly journals) whose title, abstract or key word was in English and matched those search terms, from the earliest 
date available to the present. The pilot search included ‘patient mobility’ but it generated over 6000 articles with 
many of them using ‘patient mobility’ in a clinical sense (cancer patients' physical ability to move following treatment). 
That search term was left out in the initial stage. A total of 2975 articles were finally included for screening (includ-
ing duplicates among different electronic databases [see Table 1]). We undertook a hand search and added relevant 
articles not identified within the search strategy. In the screening stage, articles whose title, abstract or key word had 
direct relevance to cross-border cancer treatments were included and the remaining went through a full-text search 
for further clarification. We reviewed full articles available in English. For inclusion, articles needed substantial cover-
age of transnational cancer and oncology treatment. This would necessarily exclude domestic focused discussions of 
cancer treatment, and we also excluded articles that listed oncology as one treatment amongst many (e.g., in broader 
discussions of medical travel that encompassed fertility, dental, cosmetic, orthopaedic, ophthalmic, transplantation, 
see Figure 1).
Our approach draws on the framework of Arksey and O'Malley,16 and aims to contextualise ‘knowledge in terms 
of identifying the current state of understanding, identifying the sorts of things we know and do not know; and then 
setting this within policy and practice contexts (Results in EMBASE and Scopus focus more on the medical treatment 
than the travel aspect of the search. They were included in the dataset if the preset inclusion criteria were met.).17
Our coverage was intentionally broad, embracing clinical, health, social science and policy literature on screening, 
surgery, including transplantation, and forms of adjunct therapy (e.g., radiotherapy, chemotherapy, hormone, immu-
notherapy). The benefit of a scoping review is its ability to survey the broad range of activity and to open routes for 
further research and discussion.
2.1 | Itineraries: who travels where, for what and why?
The cartography of oncology travel is complex. There is travel into high-income countries for treatments either una-
vailable or perceived as higher quality, for example from Kuwait and UAE to North America and Europe.18–20 There are 
examples of Diasporic travel, including Korean-American travel to Korea for screening21–24 and Mexican-Americans 
returning to Mexico25; flows between places with previous colonial relations with African women travelling to Paris 
and northern France for cancer treatments26; and flows between smaller states and regional partners such as Tonga to 
New Zealand within the Pacific,27 including bilateral health agreements, for example Bahrain to Turkey.28
Regionalised flows exist within Africa to South Africa29; from Central Asia to India,14 and between Laos and 
Thailand30; Bangladesh and Singapore31; and into Malaysia and Thailand32,33 and into Jordan from neighbouring 
countries.34 Canadian, Mexican and South American patients travel to the United States for cancer treatment with 
Canadians being outsourced by their domestic health care system and most South American patients paying out of 
pocket.35–37 Intra-European flows included Italy to France,38 and Austria to Germany.39 Individual facilities in Japan,40 
Singapore,41 and India42 identify in-country travel from a range of overseas destinations for cancer treatment. There 
were reports of ‘conflict related flows’ of cancer patients from Iraq to Lebanon,43 and growing awareness of how con-
flict and dislocation impact on patients requiring cancer treatment.
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Countries could be both senders and receivers of cancer patients. For example, Kuwait acted as a treatment hub 
for expatriates44 but also sponsored its own citizens' treatment abroad, including to the UK, Germany and the United 
States.19 Similarly, the UK treated international patients from UAE20 but also outsourced paediatric treatments for its 
own citizens currently unavailable in the UK to the United States, notably Proton Beam Therapy.45,46
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Search term ProQuest Scopus Web of science EMBASE
‘Medical travel’ & cancer/tumour 6 12 13 70
‘Medical tourism’ & cancer/tumour 17 74 58 71
Treatment & overseas/abroad & cancer/tumour 197 733 343 913
Cross-border & care & cancer/tumour 13 29 23 39
Cross-border & travel & cancer/tumour 2 5 6 10
‘Foreign country’ & cancer/tumour 10 161 10 160
Total (including duplicates) 245 1014 453 1263
T A B L E  1  Key search terms and databases
F I G U R E  1  PRISMA flow diagram for the scoping review process
There was little robust evidence on precise traveller numbers, aside from limited self-reports at the provider lev-
el30,41,42 and, occasionally, figures of Gulf Government sponsorship programmes.19,20 It is not straightforward to iden-
tify patient numbers, episodes of care, time periods spent overseas, and costs of treatment. Treatments are funded 
by individuals out of pocket and through family support including travel for screening but also encompassing long-
term term expensive treatments including from LMIC countries into developed health care systems and from conflict 
zones to neighbouring countries,26,34,43 and via established state-sponsored programmes such as those from the Gulf 
States.18–20 There were few examples of travel funded by private or occupational insurance; an exception being Afri-
can regional travel for breast cancer treatment, with 70% of patients utilising private insurance.29
The full range of treatments and therapies was reflected in the literature we found and included: screening22–24; 
surgery30; radiation30,36,45,47; chemotherapy30,47; and transplantation of organs48,49 and bone marrow28 but with few 
discernible patterns (Liver transplantation is a treatment for Hepatocellular carcinoma). Similarly, travel was for all 
types of cancer sites including: prostate36; breast,29,37,50 colorectal21; lymphoma50; cervical23,47; and brain.45 The focus 
of articles was primarily curative, but some identified palliative care within treatment pathways.25,32,51–53
Around 20 articles (clinical cases, legal, ethical and policy discussions) focused on paediatric oncology, frequently 
linked to Proton Beam Therapy including national travel policy for the UK,45 Denmark,54 and Ireland.55 There was 
related coverage of treatment abroad for rare childhood cancers.35,39,41,56 Single clinical case reports in paediatric ser-
vices and adult services, identified adverse effects and complications of travel, including misdiagnosis,57 and risks 
from experimental live therapeutic agents58 and Complementary and Alternative Treatments.59
Patient motivations for travelling abroad were second opinions on diagnosis and treatment.14,18,26,53,60 Some pa-
tients accessed treatments that were unavailable in the home country either because they were not approved despite 
being routinely available in other countries [for example, Proton Beam Therapy59] or because they were experimental 
and alternative therapeutics that fell outside accepted treatments for which there was no evidence of clinical effi-
cacy and safety.58,61 Patients also travel for standard treatments that are not available within the domestic health 
system including regionalised travel for example where services are offered in South Africa and Jordan to those in 
neighbouring countries.29,34,43 Patients were motivated to seek what they perceived as better quality services abroad 
which include travel by Korean Americans to Korea for screening and intra-European flows,19,20,23,38 coupled with a 
lack of confidence in services available at home, something for example noted regarding patient outflows from Gulf 
states.19,20 Identifying those travelling because they need truly specialised care only available abroad, and those who 
still choose to travel despite services being available locally is contentious.18 Familiarity with a health system was 
important motivation for undergoing screening and receiving some treatments.23,24,52 Travel decisions may ultimately 
rest on multiple motivations. Aside from screening,23 travelling explicitly for cost or privacy reasons were not detailed 
within the literature as primary motivations.
2.2 | Treatment processes and challenges
Travel decisions involve clinical networks and referral pathways which may include relationships between clinical 
centres when services are unavailable in one country due to size, cost or lack of specialisation.28,39,45 Clinicians may 
also make informal suggestions to patients for further treatment options, drawing on experience of previous clinical 
residency or overseas connections.26 Travel decisions may be contra to local clinical advice where domestic clinical 
teams do not support, and may counsel against, travel abroad by an adult or child patient.18,62 Conversely, there is also 
some reporting of patients choosing not to travel abroad for chemotherapy and radiotherapy despite such treatment 
overseas being advised by local clinicians as part of a continuous treatment pathway.47 Family took a key role in deci-
sion-making for adult cancer patients,14,19,29 and word of mouth and acquaintance with others previously treated in a 
facility was also a factor in decision making for both screening and treatment intervention.23,29 There was little explic-
it discussion of brokerage and intermediaries within decision-making, travel and treatment arrangements. Analysis 
of provider literature marketing the range of medical treatments identified standard cancer treatments as the most 
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prevalently marketed of all clinical specialities,63,64 and the literature on ethnic media marketing has a role in informing 
decisions for cancer screening.23
Culturally competent care,18,35,40,44,53 including language and ability to communicate complex medical issues 
during treatment, was highlighted as a fundamental concern.28,35,56 In a survey of overseas cancer patients treat-
ed in India42 nearly 93% of respondents identified issues with language and food. Continuity of care and sharing of 
medical information was seen as a challenge within treatment pathways whether for screening, surgery or radiog-
raphy23,29,36,37,40 including complexity of returning patients back home for palliative care and end of life care given 
domestic deficiencies in healthcare53 and an example of end of life care received out of jurisdiction.32
Detailed qualitative studies explore the experience of travel and treatment, including for patients and their fami-
lies.34,45,56 Absence from home may be through temporary relocation or through continuous movement back and forth 
for treatments such as radiography.14,26,37,45,56 There are reported difficulties in parenting abroad during paediatric 
treatment35,56 but also benefits from being absent from the demands of home-life and in the support available over-
seas.36,45,56 Perhaps not surprisingly, there are significant financial costs of self-payers seeking treatment.14,26,34,41 
Wider family impacts of treatment included family members taking leave without pay and quitting jobs,41 and ‘finan-
cial toxicity’43 in conflict related settings may involve sale of homes and possessions to fund treatments.
2.3 | Patient safety, risk and outcomes
Given time sensitivity of treatment for cancers, there are identified risks in eschewing local based treatment and 
waiting for travel approval and arrangements in order to continue treatment abroad.14,18,19,54 Aside from standard 
treatments, risks were discussed around particular Complementary and Alternative Treatments59,61 and experimental 
treatments58 given a lack of evidence of efficacy and regulation. There were discussions of the evidence-base for more 
standard – albeit locally unavailable – interventions, notably Proton Beam Therapy.65
The gold standard of cancer outcomes reporting is survival and recurrence rates – although clearly quality of 
care is irreducible to these. There is discussion of clinical benefits being balanced with potential disruption that travel 
overseas could cause.66,67 Little is known about the relative clinical outcomes for particular treatments, institutions, 
clinicians and localities. There is scant evidence on long or short-term follow-up of patients dispersing to home coun-
tries following treatments and the financial cost of states supporting the treatment of patients abroad. Only within 
clinical trials is randomisation feasible and the possibility of standard outcomes design studies. Some rarer cancers 
present difficulties for clinical trials with small numbers, and determining appropriate measures and timeframes are 
problematic.
There were some limited reports of follow up and positive early outcomes of particular interventions, for example 
a cohort of those treated with Proton Beam Therapy.68 There are reports from Canada of differences in the delivery 
of treatments when similar services are received at home or outsourced to the United States.69 For screening, there 
is evidence that medical travel leads to greater uptake for some migrant groups travelling from the United States 
to Korea.21,22,24 Elsewhere, transplant outcomes of travel from Hong Kong to China, with survival rates lower than 
local treatment but comparable to international ones, are reported.49 The importance of further outcomes research 
is widely acknowledged including within transplantation programmes,28 and radiotherapy,69 but is a major gap in the 
existing literature, alongside our limited knowledge of patient safety and quality of care.
2.4 | Ethical, legal and regulatory considerations
Ethical issues include the impact of medical travel on doctor and patient relations, as well as the health system impli-
cations for both sender and receiving country.
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There are reports that patient-doctor conflict may emerge during referral, for example in patients requesting 
medical reports from home doctors to affirm that the cancer treatment is not available locally, when in fact such care is 
available.18 Correspondingly, patients may press upon clinicians in treating countries to receive letters allowing them 
to return for follow-up treatments that are then funded by their domestic healthcare system.53 Difficulties of ensuring 
informed consent in decision-making are identified where complex care is being delivered overseas.19,53,70 Interests 
of the patient, patient autonomy, conflict of interest, and fairness raise further ethical questions.53 Treatment within a 
commodified relationship has the potential to generate financial conflicts of interest.18
Patients' families may request that the treating physician not disclose the cancer diagnosis to the patient.18,53 
The precise role of home doctors in offering advice for prospective travellers is contentious for forms of cancer treat-
ments, as it is with all travel abroad for medical treatment.49 The nature of cancer pathology also generates specific 
dilemmas, including where travel for treatment at a late staging of the disease47,71 may be accompanied by unrealistic 
expectations of what intervention can achieve.53
Health system questions for destination countries include whether providing cancer treatments – across private 
and public facilities – to international patients do cross subsidise and benefit local populations, or whether incoming 
patients are a drain on resources and facilities.53
For home healthcare system implications, articles are replete with the fundamental questions of who gets access, 
to what and how? Resource implications include the public costs of those seeking treatment and follow-up treatment 
overseas,30,53 resource allocation decisions, including elites having priority access to travel support,72 and corruption 
within decision-making.19 Decisions to seek treatment abroad that are borne from mistrust of local care19,30 raise fun-
damental questions about the relationship between governments and their citizens.
There are reports about legal concerns related to treatments that are currently non-funded or non-standard 
treatments,62,65,73 including those that are experimental, complementary and alternative medicine,59,61 and the ad-
vertising of treatments.74 There is some debate on the regulation of stem/gene experimental interventions, including 
the lack of evidence for advertised treatments,75 and the regulation of clinics that offer diverse treatments including 
for cancer.61,76
3 | DISCUSSION
This review has identified a variety of articles and commentaries around transnational oncology treatment: a rich 
vein of single case-note discussions, analysis of administrative data, and detailed coverage of motivations, treatment 
processes and travel experiences. Largest volumes of flows do not garner most coverage; there is inverse coverage of 
some childhood cancer-related treatments, particularly Proton Beam Therapy. There are also sizeable flows about 
which little is known, including travel to and from the Middle East but also concerning flows within the Asia region. 
Studies related to cancer screening mainly focus on Korean-Americans. The picture of transnational oncology treat-
ment (patient numbers, cancer diagnosis, treatment options) remains sketchy. This is perhaps surprising given analysis 
of provider literature marketing medical treatments to overseas patients suggests standard cancer treatments are the 
most prevalently marketed of all clinical specialities. Within broader coverage of medical treatment abroad, a number 
of reported studies do mention cancer treatment but relatively few studies focus on cancer patients and their path-
ways and experiences in detail. For example, specialist London hospitals deliver cancer treatments to international 
patients but within the academic literature there is little coverage of cancer treatment experience per se.77
Three travel itineraries are identifiable. First, individual travellers to treatment centres, drawing upon knowledge 
of acquaintances, and family and friends. Second, patients formally referred by their treating clinician and health sys-
tem (for both standard treatments and emerging technologies). Third, those who receive services abroad, typically 
screening, but for whom treatment is a less primary rationale for travel.21,23
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We can glean relatively little from published literature about South East Asia, but anecdotal understandings 
alongside some detailed empirical study of particular providers and cases (e.g., in Malaysia, Thailand and Singapore) 
do point to cancer treatments being delivered in these settings, including palliative care.31,32
A clear limitation of the study being undertaken in English is its tendency to overlook activity relating to China 
and it is imperative to understand better such travel itineraries around screening and treatment. Our own work ac-
knowledges a growing middle class in China looking to travel for services not easily available at home. For example, 
2018 saw a huge rise in demand from Chinese patients for the HPV vaccine to protect girls and young women against 
cancers administered at private clinics. Estimates suggest that 2016–2018 two million women travelled to Hong Kong 
from China for HPV vaccinations.78
The burden of breast cancer in low-income and middle-income countries will increase dramatically in the coming 
decades, raising questions about access and equity for cancer care. In 2017, 26% of low-income countries reported 
having no public pathology services1 and this could accelerate travel for diagnosis and screening for those with suffi-
cient financial resources. Better understanding the experiences relating to LMIC countries and Central and Eastern 
European states will also shape a fuller picture of transnational oncology treatment.
Alongside such geographical blind spots, we identify local, national and global questions which together would 
deepen our understanding of the totality of transnational oncology treatment. Local: We must better understand cur-
rent travel patterns and other drivers including the motivations, decision-making, and metrics and guides to quality 
underpinning travel to and from particular places. Such studies should examine the social context of decisions and 
treatment, highlighting lay referral and support networks, travel companions, and wider family and community contri-
butions that are practical, financial and emotional. There are knowledge gaps in the understanding of doctor-patient 
relationships, including ethical dilemmas of cancer treatments abroad that embrace communication, family role and 
culture. Insight into how commercialization and commodification (by clinics, hospital and aftercare settings) shape 
patients' experiences is needed. In short, we must contextualise cancer travel to understand health politics, health sys-
tems and provider behaviour in relation to the aims of quality healthcare: safety, effectiveness, patient-centeredness, 
timeliness, efficiency, and equity.79
Better understanding about treatment decisions and continuity of care between home and destination countries 
will illuminate how transnational care relationships develop perhaps over many months, or even years [see80]. This in-
cludes how cancer treatment is enmeshed in transnationalism; including expatriates treated overseas then returning 
home43 and the role of diasporic flows, and networks. Cross-country coordination of health care services, patient-cli-
nician communication surrounding overseas care-seeking behaviour, and post-treatment implications are areas that 
would benefit from health service research.37
Relatively little is known about the up-take and experiences of experimental treatments, including informa-
tion provided on these treatments and how it is understood, how such treatments are promoted, and patient deci-
sion-making. Regulatory divergence between home and overseas countries around prevention and screening, coupled 
with fast-moving developments such as ‘liquid biopsy’ or emerging protective treatments, could generate rapid flows. 
We must be alert to these emerging developments and the health benefits and costs, both at the individual and popu-
lation level, that they generate in the short and longer term.
National questions coalesce around the financial and non-financial implications (e.g., loss of trust in domestic 
healthcare) of citizens travelling abroad. Funding cancer treatments for citizens overseas must be accompanied with 
allocative transparency around access, and the costs to the public purse.
Transnational oncology treatment is sensitive to domestic eligibility criteria, domestic regulation and waiting lists, 
and any changes in these may lead to new itineraries and routes. Patients experiencing delay in accessing urgent treat-
ment will have unequal access to personal financial resources and therefore opportunities to circumnavigate waits. 
Such travel may have the effect of undermining the solidarity of healthcare provision and of reproducing or amplifying 
divisions. On the other hand, national decisions around outsourcing what are deemed fundamental treatments may 
potentially strain the contract between citizen and government, and prompt animosity from local health care profes-
sionals. Travel abroad will complicate how countries meet national cancer priorities such as screening targets.22,24
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Global: Patient travel overseas for treatment sits within the wider context of trade in cancer services80 which also 
includes: tele-health (remote diagnosis, consultation and surveillance), establishing oncology centres and providing 
training abroad, and oncology professionals relocating overseas on a temporary or permanent basis to deliver care. 
We must explore how broader health trade in cancer care impacts local populations in both source and destination 
countries. Health trade is interrelated with health diplomacy and soft power; emerging bilateral relations between 
countries may include trade and support in healthcare and specialist cancer services. This includes scrutinising their 
impact on access to health services and on global health inequalities.
Finally, the current global challenges related to the Covid-19 pandemic have knock-on effects for cancer treat-
ment and cancer travel. With patient treatment disrupted, there are potentially short and medium-term health system 
repercussions for source and destination countries.81 Whether Covid-19 serves to redraw the cartography of transna-
tional oncology mobility in the longer-term remains a moot point.
4 | CONCLUSION
There is a clear and urgent global health research agenda around transnational oncology treatment. This may be cap-
tured under five main themes. First, research on trajectories and itineraries to systematically detail the flows of patients 
and where they go, and for what treatment. Second, in depth focus on treatment decisions, experiences and outcomes, 
including understanding the experiences of innovative and more routine treatments. Third, locating patient travel 
in wider analysis and knowledge of health systems, including costs and the context of domestic and overseas provision. 
Fourth, professional perspectives, of both home and overseas clinicians, including ethical dilemmas and experience in 
ensuring continuity of care. Fifth, situating such travel within the wider context of health trade, including professional 
migration, education and training, and tele-health. Tackling such an agenda is ambitious and will necessarily involve 
collaborative relationships, with the participation of academic and clinical researchers based across all regions. It 
will also be multidisciplinary, embracing epidemiology, health economics, health policy and politics, ethics, and health 
management.
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